REG-4basebio Plc: Appointment of COO

4BasebioAnnouncement

Today 07:00

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

4basebio PLC

("4basebio" or the "Company")

4basebio                                                                      
                                                                       
strengthens operations, appointing Scott Lorimer as Chief Operating Officer
*                                                                             
                                                          Mr Scott Lorimer
will support 4basebio’s accelerated growth strategy, bringing advanced
therapy leadership experience and a track record of bringing products to
market                                                                        
                                                     
*                                                                             
                                                          Mr Lorimer brings
approximately 30 years of experience and a deep understanding of commercial
scale-up in biomanufacturing 
CAMBRIDGE, UK, 12 March 2026 –                                              
                                                                              
       4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing
and nucleic acids for next-generation therapeutics, today announces the
appointment of Scott Lorimer as Chief Operating Officer, effective
immediately.

Scott has more than 30 years’ experience in bioprocess development and
commercial manufacturing of biologics and cell and gene therapies for
oncology, rare diseases and immune disorders. Scott led bioprocess development
and good manufacturing practice (GMP) operations in small biotech start-up
companies, large biopharmaceutical innovators and global contract development
and manufacturing organisations (CDMOs). Mr Lorimer designed, built, validated
and gained regulatory approval for GMP manufacturing operations in the USA,
UK, EU and APAC.

Scott will work closely with Dr Amy Walker, 4basebio’s newly appointed Chief
Executive Officer, and the wider leadership team in an accelerated growth
strategy, transitioning the business from an R&D-driven organisation to a
rapidly growing commercial one. Scott will be responsible for scaling the
Company’s innovative synthetic DNA platform to serve its client base in the
dynamic cell and gene therapy, mRNA, and vaccine markets, overseeing
manufacturing operations, quality and regulatory compliance, process
development, and supply chain and facility management.

Dr Amy Walker, Chief                                                          
                                                        Executive Officer of
4basebio, said                                                                
                                                                    :         
                                                                              
                                                                            
“Scott brings exactly the operational leadership 4basebio needs as we expand
our synthetic DNA manufacturing capacity and focus on accelerated commercial
growth. His deep understanding of biotech operations and commitment to
quality, scalable manufacturing will help us meet the increasing demand from
customers advancing synthetic biology applications worldwide, and he will play
a crucial role in supporting me and the wider team as we advance our
commercial strategy."

Scott Lorimer, Chief Operations Officer of 4basebio, added:                   
                                                                            
“                                                                           
                                        I have spent my career developing
technical and manufacturing capabilities for advanced therapies and 4basebio
offers the perfect opportunity to join a dynamic, fast-growing and
commercially-focused company leading the revolution in synthetic DNA. The
Company is at a tipping point with an expansion of facilities well underway,
scaling operations to meet increasing customer demand for its synthetic DNA
products, and I’m looking forward to joining Amy and the team in
transitioning the business for a period of increased commercial growth."

Most recently, Scott was Senior Consultant Technical Operations at SL
BioPharma Consultants, where he was responsible for advising clients on
technical operations for GMP manufacturing of cell and gene therapies,
antibody drug conjugates, biologics and sterile blood products. Earlier in his
career, Scott led operations and manufacturing teams at Instil Bio, Catalent,
Sanofi Genzyme and Patheon. He also led the foundation of the Sanofi-Lonza
BioAtrium joint venture.

Scott joins a leadership team focused on biomanufacturing scale-up and
commercial acceleration. In February 2026, 4basebio appointed Amy Walker as
Chief Executive Officer. Amy is driving an accelerated commercial growth
strategy focusing on deepening penetration of the synthetic DNA market as
customers increasingly seek alternatives to plasmid DNA and building on the
Company’s recent GMP milestone to support clinical programmes in cell and
gene therapy and vaccine development                                          
   .

For further enquiries, please contact:

 4basebio PLC                                      +44 (0)12 2396 7943  
 Dr Amy Walker, CEO                                                     
                                                                        
 Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson / Ed Downes                                 
                                                                        
 Cavendish Capital Markets Limited (Joint Broker)  +44 (0)20 7220 0500  
 Geoff Nash / Nigel Birks                                               
                                                                        
 RBC Capital Markets (Joint Broker)                +44 (0)20 7653 4000  
 Kathryn Deegan / Matthew Coakes                                        
                                                                        
 ICR Healthcare (Media and Investor Relations)     +44 (0)203 707 5700  
 Mary-Jane Elliott / Jessica Hodgson                                    
                                                                        

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces
GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.

For more information, visit                                                   
                                                        4basebio.com          
                                   (https://www.4basebio.com/)                
                                             .

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved